Digital Clinics Research and Services Pvt Ltd

DigiClinics is an innovative AI company revolutionizing clinical diagnostics with an integrated imaging platform for end-to-end precision care. Combining AI-powered diagnostic pipelines and CAP-compliant automated workflows, we are transforming breast cancer diagnosis and care. As pioneers in Digital Pathology Imaging Diagnostics since 2020—rooted in research at Emory School of Medicine, Atlanta, USA (2017)—our global presence spans at USA-Cambridge, Cumming, San Francisco and Tech Development Centre in Hyderabad, India Our flagship solutions include: • Breast Cancer Screening: AI driven Cancer Screening using Ultrasound, GenAI generated Mammo Screening Radiologist Report, with Automated assessment and BI-RADS scoring for both Ultrasound and Mammography • Breast Cancer Histology Grading: Comprehensive imaging marker analysis for Nottingham Cancer Grading report • Subtyping and Staging: Automated assessment of ER/PR, HER2, Ki67 biomarkers Uniquely, DigiClinics goes beyond diagnosis with clinical Utilities analysing digital pathology images: • Targeted Therapy Recommendations: Predict optimal treatments and monitor therapy efficiency. • Prognostic Insights: Identify critical factors influencing patient outcomes. • Clinical Trial Enablement: Facilitate clinical trials recruitment for cutting-edge studies. • Sustainable Access: Partnering with insurers for universal, annual AI-driven screenings per WHO guidelines • Evolution Model: Our visionary 'Device Bundled with DiagAI' model partners with OEMs to bundle advanced AI with medical devices, delivering seamless, intelligent diagnostics that redefine healthcare precision and accessibility By unifying screening, diagnosis, and therapy recommendations into a single, streamlined platform, DigiClinics sets itself apart in the global digital pathology landscape. We don’t just compete—we lead in transforming breast cancer care.